Suppr超能文献

靶向肥胖相关性肾小球病中的肾近端小管细胞

Targeting Renal Proximal Tubule Cells in Obesity-Related Glomerulopathy.

作者信息

Ye Muyao, Yang Ming, Dai Wenni, Li Hao, Zhou Xun, Chen Yinyin, He Liyu

机构信息

Department of Nephrology, The Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha 410011, China.

Department of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha 410081, China.

出版信息

Pharmaceuticals (Basel). 2023 Sep 5;16(9):1256. doi: 10.3390/ph16091256.

Abstract

As a metabolic disorder, obesity can cause secondary kidney damage, which is called obesity-related glomerulopathy (ORG). As the incidence of obesity increases worldwide, so does the incidence of end-stage renal disease (ESRD) caused by ORGs. However, there is still a lack of effective strategies to prevent and delay the occurrence and development of ORG. Therefore, a deeper understanding and elaboration of the pathogenesis of ORG is conducive to the development of therapeutic drugs for ORG. Here, we review the characteristics of pathological lesions of ORG and describe the roles of lipid metabolism disorders and mitochondrial oxidative stress in the development of ORG. Finally, we summarize the current available drugs or compounds for the treatment of ORG and suggested that ameliorating renal lipid metabolism and mitochondrial function may be potential therapeutic targets for ORG.

摘要

作为一种代谢紊乱疾病,肥胖会导致继发性肾损伤,即肥胖相关性肾小球病(ORG)。随着全球肥胖发病率的上升,由ORG引起的终末期肾病(ESRD)的发病率也在增加。然而,仍然缺乏有效的策略来预防和延缓ORG的发生与发展。因此,对ORG发病机制进行更深入的理解和阐述,有助于开发针对ORG的治疗药物。在此,我们综述了ORG病理损伤的特征,并描述了脂质代谢紊乱和线粒体氧化应激在ORG发展中的作用。最后,我们总结了目前可用于治疗ORG的药物或化合物,并提出改善肾脏脂质代谢和线粒体功能可能是ORG潜在的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab09/10535317/2d3934d996be/pharmaceuticals-16-01256-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验